Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor.
- Resource Type
- Article
- Authors
- Li, Wei-Qing; Yu, Hong-Yu; Li, Yi-Ming; Wang, Xiang; He, Jin; Yan, Hong-Zhu; Yang, Dao-Hua; Wu, Xiao-Jun; Hou, Li-Jun; Liu, Hui-Min; Xia, Chun-Yan; Lu, Yi-Cheng
- Source
- Biochemical & Biophysical Research Communications. Apr2014, Vol. 446 Issue 4, p1261-1267. 7p.
- Subject
- *LEUCINE
*GLIOBLASTOMA multiforme
*DNA topoisomerase II
*GENE expression
*TUMOR growth
*MICRORNA
*PATIENTS
- Language
- ISSN
- 0006-291X
Highlights: [•] The expression levels of LRRFIP1 are higher in VM-26 treated GBM patients with long five year survival rate. [•] LRRFIP1 chemosensitizes U373MG cells to VM-26 and inhibits U373MG cell progression. [•] LRRFIP1 suppresses GBM tumor growth in vivo. [•] LRRFIP1 reverses the effect of miR-21 in VM-26 resistant on GBM cells. [Copyright &y& Elsevier]